 "Dr Reddy's gets USFDA nod for chemotherapy drug")
Hyderabad-based pharmaceutical major, Dr Reddy's Laboratories Limited, has received an approval from the United States Food and Drug Administration (US FDA) for its Azacitidine for injection 100 mg/vial.
A bioequivalent generic version of Vidaza (azacitidine for injection), Azacitidine, a chemotherapy drug, is mainly used to treat myelodysplastic syndromes (MDS). Dr Reddy’s Azacitidine for injection 100 mg/vial is available in single use-vials.
The Vidaza brand had US sales of approximately $378.5 million for the most-recent 12 months ending July 2013 according to IMS Health. The launch of product in the market is planned in the near-term, the company said in a press release on Tuesday.
Dr Reddy's scrip is currently trading at Rs 2,313.55 on the BSE, up 4.07%, over the previous close of Rs 2,223.15 a share.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%